https://orcid.org/0000-0001-8080-2596
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Although the efficacy of MSCs on the liver fibrosis is investigated, it is not exactly clear whether released molecules by MSCs are sufficient to mediate the anti-fibrotic effects or not. In this study, the possible hepatoprotective effects of human umbilical cord MSCs derived conditioned medium (UC-CM) was investigated. 30 male rats were divided into 3 groups (n = 10): C: control; F: fibrosis were intraperitoneally injected with CCl4 (1 ml/kg, i.p); F/UC-CM: fibrosis rats that received UC-CM (100 µg/kg, i.v). At the end of the 12th week, serum and liver samples were collected to analyze biochemical, molecular, and histopathological parameters. In comparison with CCl4 intoxicated animals, the results showed a significant amelioration of weight loss, histological changes as well as attenuation of serum activity of ALT, AST, and ALP in F/UC-CM. The liver hydroxyproline content was significantly reduced by UC-CM treatment. Accordingly, improvement in oxidative parameters such as MDA, TAC, and TOS was also observed in the F/UC-CM group. UC-CM administration down-regulated gene expression of TGF-β1, TNF-α, TβRII, MMP-2, and MMP-9 as well as the protein level in TGF-β1 and TNF-α. Immunohistochemical analysis showed a notable lower hepatic α-SMA expression in the F/UC-CM group. In conclusion, these findings revealed that the remarkable hepatoprotective property of UC-CM could lend support to its anti-inflammatory and antioxidative and anti-fibrotic effects.
Disclosure statement
No conflict of interest is declared by the authors.